Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MLS-101-901 Open-Label Extension Study of Lorundrostat in Hypertension
2023-508670-28-00Phase 3Authorised
- Sponsor
- Mineralys Therapeutics
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial of lorundrostat in hypertension (HTN) (3 arms), sponsored by Mineralys Therapeutics. Primary endpoints: Long-term maintenance of antihypertensive effect, RTW substudy SBP change and 4 more. Planned start Aug 2024; status: authorised.
02
Drugs
lorundrostat
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on 2023-508670-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508670-28-00.